Anti CD20 Monoclonal Antibody (Rituximab) as a Rescue Treatment in Severe and Refractory SLE

Al-Omary, Hanan L.; Alawad, Zainab M.; Bernieh, Bassam

doi:10.13005/bpj/1394

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab is an effective treatment in patients with life-threatening acute hemolytic anemia. [ 114 , 115 , 116 ]…”

Section: Guideline Development Methodsmentioning

confidence: 99%

“…Rituximab is an effective treatment in patients with life-threatening acute hemolytic anemia. [114][115][116] Recommendation 9: Patients with severe or refractory SLE, plasma exchange or immunoadsorption (2C) can be considered. For patients who present with refractory SLE or infection, intravenous immunoglobulin (2D) may be considered in addition to the standard treatment.…”

Section: Rituximab Nomentioning

confidence: 99%

See 1 more Smart Citation

2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus

Zhao

Zhang

et al. 2020

Rheumatology and Immunology Research

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that represents a prodigious challenge of diagnosis and treatment. In 2019, under the leadership of the Chinese Rheumatology Association, a multidisciplinary guideline development group was established to develop an evidence-based diagnosis and treatment guideline for patients with SLE in PR China. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence and the strength of recommendations. The guideline was reported following the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. In this guideline, we provided recommendations for SLE classification criteria, disease activity monitoring and assessment, medication administration and considerations for SLE patients with organs and systems involved, and management of special populations such as SLE patients in the setting of pregnancy. This guideline serves as an evidence-based tool for Chinese clinicians to diagnose and treat patients with SLE.

show abstract

“…Rituximab is an effective treatment in patients with life-threatening acute hemolytic anemia. [ 114 , 115 , 116 ]…”

Section: Guideline Development Methodsmentioning

confidence: 99%

Section: Rituximab Nomentioning

confidence: 99%